DeLong Mark Jeffrey
Insider CIK 1856078 · APLS Senior Vice President
Trades across companies
| Ticker | Code | Trade | Filed | Shares | Price | Value | Owned after | |
|---|---|---|---|---|---|---|---|---|
| APLS Apellis Pharmaceuticals, I | D To issuer deriv | 2026-05-14 | 2026-05-14 | 18,750 | — | $0 | 0 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | D To issuer deriv | 2026-05-14 | 2026-05-14 | 30,845 | — | $0 | 0 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | D To issuer deriv | 2026-05-14 | 2026-05-14 | 6,952 | — | $0 | 0 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | D To issuer deriv | 2026-05-14 | 2026-05-14 | 30,000 | — | $0 | 0 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | D To issuer deriv | 2026-05-14 | 2026-05-14 | 24,666 | — | $0 | 0 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | D To issuer deriv | 2026-05-14 | 2026-05-14 | 27,224 | — | $0 | 0 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | D To issuer deriv | 2026-05-14 | 2026-05-14 | 14,799 | — | $0 | 0 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | D To issuer deriv | 2026-05-14 | 2026-05-14 | 82,500 | — | $0 | 0 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | D To issuer | 2026-05-14 | 2026-05-14 | 36,606 | — | $0 | 0 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | D To issuer | 2026-05-14 | 2026-05-14 | 8,482 | — | $0 | 0 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | D To issuer | 2026-05-14 | 2026-05-14 | 4,909 | — | $0 | 0 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | D To issuer | 2026-05-14 | 2026-05-14 | 36,606 | — | $0 | 0 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | D To issuer | 2026-05-14 | 2026-05-14 | 18,303 | — | $0 | 0 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | A Award | 2026-05-14 | 2026-05-14 | 18,303 | — | $0 | 18,303 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | D To issuer | 2026-05-14 | 2026-05-14 | 21,381 | — | $0 | 0 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | A Award | 2026-05-14 | 2026-05-14 | 36,606 | — | $0 | 36,606 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | D To issuer | 2026-05-14 | 2026-05-14 | 19,006 | — | $0 | 0 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | A Award | 2026-05-14 | 2026-05-14 | 19,006 | — | $0 | 19,006 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | D To issuer | 2026-05-14 | 2026-05-14 | 41,250 | — | $0 | 0 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | A Award | 2026-05-14 | 2026-05-14 | 41,250 | — | $0 | 41,250 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | U Tender | 2026-05-14 | 2026-05-14 | 114,591 | — | $0 | 0 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | S Sale | 2026-02-11 | 2026-02-13 | 368 | $22.15 | $8.2K | 114,591 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | A Award | 2026-01-28 | 2026-01-30 | 36,606 | — | $0 | 114,959 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | S Sale | 2026-01-22 | 2026-01-23 | 3,371 | $21.77 | $73.4K | 78,353 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | S Sale | 2026-01-20 | 2026-01-21 | 1,334 | $19.79 | $26.4K | 81,724 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | S Sale | 2026-01-13 | 2026-01-15 | 1,780 | $22.19 | $39.5K | 83,058 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | A Award deriv | 2025-06-09 | 2025-06-11 | 82,500 | $19.39 | $1.60M | 82,500 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | S Sale | 2025-02-11 | 2025-02-12 | 363 | $28.54 | $10.4K | 83,945 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | S Sale | 2025-01-29 | 2025-01-30 | 365 | $29.52 | $10.8K | 84,308 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | S Sale | 2025-01-22 | 2025-01-23 | 1,396 | $30.43 | $42.5K | 84,673 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | A Award | 2025-01-21 | 2025-01-21 | 28,508 | — | $0 | 86,069 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | S Sale | 2025-01-17 | 2025-01-21 | 1,235 | $29.96 | $37.0K | 57,561 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | S Sale | 2025-01-13 | 2025-01-14 | 1,599 | $28.70 | $45.9K | 58,796 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | M Exercise deriv | 2024-08-12 | 2024-08-13 | 5,201 | — | $0 | 14,799 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | M Exercise | 2024-08-12 | 2024-08-13 | 5,201 | $13.85 | $72.0K | 60,395 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | S Sale | 2024-03-18 | 2024-03-19 | 9,913 | $56.90 | $564.0K | 54,693 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | S Sale | 2024-02-12 | 2024-02-13 | 597 | $67.77 | $40.5K | 64,606 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | S Sale | 2024-01-29 | 2024-01-31 | 367 | $64.14 | $23.5K | 65,203 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | S Sale | 2024-01-22 | 2024-01-23 | 1,384 | $65.00 | $90.0K | 65,570 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | A Award deriv | 2024-01-16 | 2024-01-17 | 24,666 | $66.30 | $1.64M | 24,666 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | A Award | 2024-01-16 | 2024-01-17 | 16,963 | — | $0 | 68,585 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | S Sale | 2024-01-16 | 2024-01-17 | 1,631 | $66.81 | $109.0K | 66,954 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | S Sale | 2023-10-23 | 2023-10-24 | 131 | $46.04 | $6.0K | 51,622 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | A Award deriv | 2023-02-21 | 2023-02-22 | 7,489 | — | $0 | 7,489 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | A Award | 2023-02-21 | 2023-02-22 | 5,280 | — | $0 | 51,782 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | F Tax w/h | 2023-02-21 | 2023-02-22 | 441 | $58.50 | $25.8K | 51,341 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | F Tax w/h | 2023-02-10 | 2023-02-14 | 670 | $51.21 | $34.3K | 46,502 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | F Tax w/h | 2023-01-27 | 2023-01-30 | 367 | $52.77 | $19.4K | 47,172 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | F Tax w/h | 2023-01-20 | 2023-01-24 | 1,149 | $52.05 | $59.8K | 47,539 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | A Award deriv | 2023-01-12 | 2023-01-17 | 30,845 | $52.66 | $1.62M | 30,845 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | A Award | 2023-01-12 | 2023-01-17 | 19,634 | — | $0 | 48,688 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | F Tax w/h | 2022-10-20 | 2022-10-24 | 196 | $58.00 | $11.4K | 29,054 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | M Exercise deriv | 2022-08-17 | 2022-08-18 | 5,000 | — | $0 | 0 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | S Sale | 2022-08-17 | 2022-08-18 | 5,000 | $69.50 | $347.5K | 29,250 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | M Exercise | 2022-08-17 | 2022-08-18 | 5,000 | $15.52 | $77.6K | 34,250 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | M Exercise deriv | 2022-08-11 | 2022-08-12 | 5,000 | — | $0 | 5,000 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | S Sale | 2022-08-11 | 2022-08-12 | 5,000 | $67.00 | $335.0K | 29,250 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | M Exercise | 2022-08-11 | 2022-08-12 | 5,000 | $15.52 | $77.6K | 34,250 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | M Exercise deriv | 2022-08-08 | 2022-08-09 | 5,000 | — | $0 | 10,000 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | M Exercise | 2022-08-08 | 2022-08-09 | 5,000 | $15.52 | $77.6K | 34,250 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | S Sale | 2022-08-08 | 2022-08-09 | 5,000 | $64.50 | $322.5K | 29,250 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | M Exercise deriv | 2022-08-04 | 2022-08-08 | 10,000 | — | $0 | 15,000 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | S Sale | 2022-08-04 | 2022-08-08 | 5,000 | $62.00 | $310.0K | 29,250 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | S Sale | 2022-08-04 | 2022-08-08 | 5,000 | $59.50 | $297.5K | 34,250 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | M Exercise | 2022-08-04 | 2022-08-08 | 10,000 | $15.52 | $155.2K | 39,250 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | M Exercise deriv | 2022-07-27 | 2022-07-28 | 5,000 | — | $0 | 25,000 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | S Sale | 2022-07-27 | 2022-07-28 | 5,000 | $57.00 | $285.0K | 29,250 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | M Exercise | 2022-07-27 | 2022-07-28 | 5,000 | $15.52 | $77.6K | 34,250 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | M Exercise deriv | 2022-07-19 | 2022-07-21 | 5,000 | — | $0 | 30,000 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | S Sale | 2022-07-19 | 2022-07-21 | 5,000 | $56.42 | $282.1K | 29,250 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | M Exercise | 2022-07-19 | 2022-07-21 | 5,000 | $15.52 | $77.6K | 34,250 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | M Exercise deriv | 2022-06-16 | 2022-06-21 | 10,000 | — | $0 | 20,000 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | S Sale | 2022-06-16 | 2022-06-21 | 10,000 | $41.79 | $417.9K | 29,250 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | M Exercise | 2022-06-16 | 2022-06-21 | 10,000 | $13.85 | $138.5K | 39,250 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | M Exercise deriv | 2022-04-20 | 2022-04-22 | 7,000 | — | $0 | 35,000 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | S Sale | 2022-04-20 | 2022-04-22 | 7,000 | $52.53 | $367.7K | 28,481 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | M Exercise | 2022-04-20 | 2022-04-22 | 7,000 | $15.52 | $108.6K | 35,481 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | A Award deriv | 2022-02-10 | 2022-02-14 | 6,952 | — | $0 | 6,952 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | A Award | 2022-02-10 | 2022-02-14 | 4,901 | — | $0 | 28,481 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | F Tax w/h | 2022-02-10 | 2022-02-14 | 271 | $47.12 | $12.8K | 23,580 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | F Tax w/h | 2022-01-28 | 2022-02-01 | 434 | $38.59 | $16.7K | 20,530 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | A Award deriv | 2022-01-21 | 2022-01-25 | 15,024 | — | $0 | 15,024 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | A Award deriv | 2022-01-21 | 2022-02-07 | 19,735 | — | $0 | 19,735 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | A Award | 2022-01-21 | 2022-01-25 | 10,592 | — | $0 | 20,964 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | A Award | 2022-01-21 | 2022-02-07 | 13,913 | — | $0 | 24,285 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | A Award | 2021-10-20 | 2021-10-27 | 882 | — | $0 | 10,372 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | M Exercise deriv | 2021-07-21 | 2021-07-22 | 1,000 | — | $0 | 42,000 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | M Exercise | 2021-07-21 | 2021-07-22 | 1,000 | $15.52 | $15.5K | 10,490 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | S Sale | 2021-07-21 | 2021-07-22 | 1,000 | $65.00 | $65.0K | 9,490 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | M Exercise deriv | 2021-07-15 | 2021-07-16 | 1,000 | — | $0 | 43,000 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | M Exercise | 2021-07-15 | 2021-07-16 | 1,000 | $15.52 | $15.5K | 10,490 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | S Sale | 2021-07-15 | 2021-07-16 | 1,000 | $62.30 | $62.3K | 9,490 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | M Exercise deriv | 2021-06-15 | 2021-06-16 | 4,000 | — | $0 | 44,000 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | M Exercise | 2021-06-15 | 2021-06-16 | 4,000 | $15.52 | $62.1K | 13,490 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | S Sale | 2021-06-15 | 2021-06-16 | 4,000 | $64.96 | $259.8K | 9,490 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | M Exercise deriv | 2021-05-18 | 2021-05-19 | 2,000 | — | $0 | 48,000 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | M Exercise | 2021-05-18 | 2021-05-19 | 2,000 | $15.52 | $31.0K | 11,490 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | S Sale | 2021-05-18 | 2021-05-19 | 2,000 | $55.00 | $110.0K | 9,490 | SEC↗ |